{"url_path":"/sec/irdm/8-k/2026-06-29/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1418819/0001104659-26-078482-index.html","accession_number":"0001104659-26-078482","cik":"0001418819","ticker":"IRDM","issuer_name":"Iridium Communications Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1418819/0001104659-26-078482-index.html","primary_entity_key":"0001418819","primary_entity_name":"Iridium Communications Inc."},"word_count":1664,"has_tables":true,"body_markdown":"**Item 7.01. Regulation FD Disclosure.**\n\n \n\nOn June 29, 2026, Iridium and Rocket Lab issued a joint press\nrelease announcing execution of the Merger Agreement. A copy of the joint press release is attached hereto and furnished herewith as Exhibit 99.1.\n\n \n\nIn addition, on June 29, 2026, Iridium and Rocket Lab released\na joint investor presentation, which includes supplemental information about the proposed transaction. A copy of the joint investor presentation\nis attached hereto and furnished herewith as Exhibit 99.2.\n\n \n\nThe information set forth under this Item 7.01, Exhibit 99.1\nand Exhibit 99.2 is not being filed for purposes of Section 18 of the Exchange Act and is not to be incorporated by reference\ninto any filing of the registrant under the Securities Act or the Exchange Act, whether made before or after the date hereof,\nregardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in\nsuch a filing.\n\n \n\n**Additional Information and Where to Find\nIt**\n\n \n\nThis communication is being made in respect of a proposed transaction\ninvolving Rocket Lab and Iridium. In connection with the proposed transaction, Rocket Lab will file with the SEC a Registration Statement\non Form S-4 that includes the proxy statement of Iridium that will also constitute a prospectus of Rocket Lab. When the proxy statement/prospectus\nis finalized, it will be sent to the stockholders of Iridium seeking their approval of certain transaction-related proposals. This communication\nis not a substitute for the proxy statement/prospectus or any other documents which Rocket Lab or Iridium may file with the SEC in connection\nwith the proposed transaction.\n\n \n\nRocket Lab may not sell the common stock referenced in the proxy statement/prospectus\nuntil the Registration Statement on Form S-4 filed with the SEC becomes effective. The preliminary proxy statement/prospectus and\nthis communication are not offers to sell any securities, are not soliciting an offer to buy any securities in any state where the offer\nand sale is not permitted and are not a solicitation of any vote or approval.\n\n \n\n \n\n \n\n \n\nROCKET LAB AND IRIDIUM URGE INVESTORS AND SECURITY HOLDERS TO READ\nTHE REGISTRATION STATEMENT ON FORM S-4, THE RELATED PROXY STATEMENT/PROSPECTUS INCLUDED THEREIN AND OTHER DOCUMENTS FILED WITH THE\nSEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.\n\n \n\nInvestors and security holders will be able to obtain these materials\n(when they are available and filed) free of charge at the SEC’s website, www.sec.gov. Copies of documents filed with the SEC by\nRocket Lab (when they become available) may be obtained free of charge on Rocket Lab’s website at https://investors.rocketlabcorp.com/financial-information/sec-filings\nor by contacting Rocket Lab’s Investor Relations Department at investors@rocketlabusa.com. Copies of documents filed with the SEC\nby Iridium (when they become available) may be obtained free of charge on Iridium’s website at https://investor.iridium.com/sec-filings\nby contacting Iridium’s Investor Relations Department at investor.relations@iridium.com.\n\n \n\n**Participants in the Solicitation**\n\n \n\nRobert H. Niehaus, Louis M. Alterman, Thomas C. Canfield, Matthew J.\nDesch, Thomas J. Fitzpatrick, L. Anthony Frazier, Suzanne E. McBride, Eric T. Olson, Kay N. Sears, Monique S. Shivanandan and Jacqueline\nE. Yeaney, all of whom are members of Iridium’s board of directors, and Vincent\nJ. O’Neill, Iridium’s chief financial officer, may be considered participants in Iridium’s\nsolicitation. Information regarding such participants, including their direct or indirect interests, by security holdings or otherwise,\nwill be included in the proxy statement/prospectus and other relevant documents to be filed with the SEC in connection with the transaction.\nAdditional information about such participants is available under the captions “Proposal 1 – Election of Directors,”\n“Director Compensation” and “Security Ownership of Certain Beneficial Owners and Management” in Iridium’s\ndefinitive proxy statement in connection with its 2026 Annual Meeting of Stockholders (the “2026 Proxy Statement”), which\nwas filed with the SEC on April 2, 2026 (which is available at https://www.sec.gov/ix?doc=/Archives/edgar/data/0001418819/000141881926000022/irdm-20260402.htm),\nas well as on Iridium’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the\nSEC on February 12, 2026 (the “2025 10-K”) and certain of Iridium’s Quarterly Reports on Form 10-Q and Current\nReports on Form 8-K. To the extent that holdings of Iridium’s securities have\nchanged since the amounts printed in the 2026 Proxy Statement, such changes have been or will be reflected on Statements of Change in\nOwnership on Form 4 filed with the SEC (which are available at https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001418819).\nInformation regarding Iridium’s transactions with related persons is set forth in the\n2026 Proxy Statement under the caption “Transactions with Related Parties,” as well as on the 2025 10-K and certain of Iridium’s\nQuarterly Reports on Form 10-Q and Current Reports on Form 8-K. Certain illustrative information regarding the payments to that\nmay be owed, and the circumstances in which they may be owed, by Iridium to its named executive\nofficers in a change of control of Iridium is set forth in the 2026 Proxy Statement under\nthe caption “Severance and Change in Control-Related Benefits,” as well as on the 2025 10-K and certain of Iridium’s\nQuarterly Reports on Form 10-Q and Current Reports on Form 8-K. Rocket Lab may also be deemed to be a participant in Iridium’s\nsolicitation; information regarding Rocket Lab will be included in the proxy statement/prospectus and other relevant documents to be filed\nwith the SEC in connection with the transaction. Copies of these documents may be obtained, free of charge, from the SEC or Iridium\nas described in the preceding paragraph.\n\n \n\n \n\n \n\n \n\n**Cautionary Note Regarding Forward-Looking\nStatements**\n\n \n\nThis communication contains “forward-looking\nstatements” within the meaning of the federal securities laws. These forward-looking statements are based on Rocket Lab’s\nand Iridium’s current expectations, estimates and projections about the expected date of closing of the proposed transaction and\nthe potential benefits thereof, its business and industry, management’s beliefs and certain assumptions made by Rocket Lab and Iridium,\nall of which are subject to change. In this context, forward-looking statements often address expected future events, including future\nbusiness and financial performance and financial condition. All forward-looking statements by their nature address matters that involve\nrisks and uncertainties, many of which are beyond our control, and are not guarantees of future results, such as statements about the\nconsummation of the proposed transaction and the anticipated benefits thereof. These and other forward-looking statements are not guarantees\nof future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those\nexpressed or implied in any forward-looking statements. Accordingly, there are or will be important factors that could cause actual results\nto differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements\nand caution must be exercised in relying on forward-looking statements. Important risk factors that may cause such a difference include,\nbut are not limited to: (i) the completion of the proposed transaction on anticipated terms and timing, or at all, including obtaining\nstockholder and regulatory approvals and satisfying other conditions to the completion of the transaction; (ii) the occurrence of\nany event, change or other circumstances that could give rise to the termination of the merger agreement, including the receipt by Iridium\nof an unsolicited proposal from a third party; (iii) failure to realize the anticipated benefits of the proposed transaction on a\ntimely basis or at all, including anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses,\nearnings, the integration of the businesses of Rocket Lab and Iridium, synergies, economic performance, indebtedness, financial condition,\nlosses, future prospects, business and management strategies for the management, expansion and growth of Rocket Lab’s and Iridium’s\nbusinesses; (iv) Rocket Lab’s and Iridium’s ability to implement their business strategies; (v) potential litigation\nrelating to the proposed transaction that could be instituted against Rocket Lab, Iridium or their respective directors, managers,\nor officers, including the effects of any outcomes related thereto; (vi) the risk that disruptions from the proposed transaction\nwill harm Rocket Lab’s or Iridium’s businesses, including current plans and operations, or will otherwise divert management\ntime from ongoing business operations on transaction-related issues; (vii) the ability of Rocket Lab or Iridium to retain and hire\nkey personnel; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion\nof the proposed transaction; (ix) fluctuations in, and uncertainty as to the long-term value of, Rocket Lab or Iridium common stock\n(including as relating to the risk that any announcements related to the proposed transaction could have adverse effects on the market\nprice of such stock); (x) legislative, regulatory and economic developments affecting Rocket Lab’s and Iridium’s businesses,\nincluding actions by government agencies and third parties; (xi) general economic and market developments and conditions, potential\nchanges to international trade relations, geopolitical conflicts and effects from global pandemics, epidemics, or other public health\ncrises; (xii) the evolving legal, regulatory and tax regimes under which Rocket Lab and Iridium operate; (xiii) restrictions\nduring the pendency of the proposed transaction that may impact Rocket Lab’s or Iridium’s ability to pursue certain business\nopportunities or strategic transactions; (xiv) unexpected costs, charges or expenses resulting from the proposed transaction; (xv) risks\nthat any debt or other financing anticipated in connection with the proposed transaction is not obtained or that such financing cannot\nbe obtained on the anticipated timing or terms or unexpected costs or expenses in connection therewith; and (xvi) the other risks\nand uncertainties, as described in the periodic reports that Rocket Lab and Iridium file with the SEC. These risks, as well as other risks\nassociated with the proposed transaction, are more fully discussed in the proxy statement/prospectus to be filed with the SEC in connection\nwith the proposed transaction. Neither Rocket Lab nor Iridium assumes any obligation to publicly provide revisions or updates to any forward-looking\nstatements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise\nrequired by securities and other applicable laws. Forward-looking statements included in this communication are made as of the date of\nthis communication."}